Mounjaro英国大幅涨价引担忧，患者转向替代疗法风险与应对
Eli Lilly, the manufacturer of the weight-loss drug Mounjaro, has announced a significant price increase of up to 170% in the UK starting this autumn. While the NHS will be shielded, most patients purchase Mounjaro privately at approximately £200 per month for the highest dose. This price hike has prompted concerns among patients and pharmacies, with warnings issued against bulk buying or purchasing from unlicensed sellers due to potential supply disruptions and safety risks. Patients are advised to consult their prescribers for safe care and management of concerns.
The impending price rise is causing distress among users, some of whom are stocking up on the medication. This situation has also led to a surge in interest for Wegovy, a less effective but cheaper alternative from Novo Nordisk. Pharmacies are receiving numerous inquiries from both patients and pharmacists about safely switching from Mounjaro to Wegovy, though switching is not clinically advised without proper consultation. Some pharmacies are exploring rebate schemes to mitigate the price increase for patients.
Concerns are also raised about potentially unsafe practices like microdosing Mounjaro, which can reduce efficacy and increase infection risk. The transition from Mounjaro to other treatments is complex, especially for patients midway through their weight-loss journey who have experienced significant benefits. The affordability of continued treatment remains a critical issue for many, as they do not always fall within the NHS eligibility criteria.
网友讨论